Endocrinology Today—April 14, 2026

This week’s Endocrinology update highlights regulatory clearances, commercial launches, device innovation, preclinical progress, and expanding competition across metabolic and bone health care.

In Today’s Newsletter

Dive deeper

🦴 Apotex DENOZA approved in Canada [1] [Canada • 07 Apr 2026]

https://www.prnewswire.com/news-releases/apotex-strengthens-osteoporosis-care-in-canada-with-health-canadas-approval-of-denoza-a-denosumab-biosimilar-302735101.html
Context: Apotex Inc. said Health Canada approved DENOZA (denosumab injection), a biosimilar to Prolia, including use in high-risk postmenopausal women and men with osteoporosis.
Key point: The product is authorized for the reference biologic’s remaining indications per the product monograph and will be offered as a prefilled syringe.
Implication: Introduces competition that may affect pricing and formulary access.

💉 Biocon launches Bosaya and Aukelso in the US [2] [US • 07 Apr 2026]

https://www.biocon.com/biocon-announces-u-s-commercial-launch-of-bosaya-and-aukelso-denosumab-biosimilars/
Context: Biocon launched Bosaya (biosimilar to Prolia) and Aukelso (biosimilar to Xgeva) nationwide in the US after prior FDA approval and interchangeable designation.
Key point: The company positioned the launches as an expansion of its biosimilars footprint across osteoporosis, bone metastasis and giant cell tumor of bone use settings.
Implication: Introduces competition that may affect pricing and formulary access.

🤖 Insilico Medicine advances ISM6200 [3] [08 Apr 2026]

https://www.news-medical.net/news/20260408/Insilico-Medicine-nominates-AI-driven-drug-candidate-for-cancer-Cushings-syndrome-and-obesity.aspx
Context: Insilico Medicine nominated ISM6200, a preclinical NR3C1 inhibitor, for ovarian cancer, hypercortisolism (Cushing’s syndrome) and obesity.
Key point: The company reported preclinical efficacy signals, lower projected drug-drug interaction risk and combination potential, including with paclitaxel and semaglutide.
Implication: Signals pipeline investment and modality expansion.

📚 Fast-Track Health and MDPI start a new journal [4] [09 Apr 2026]

https://www.eurekalert.org/news-releases/1123461
Context: Fast-Track Health announced the Journal of Fast-Track Health with MDPI as publishing partner, focused on communicable disease, non-communicable disease and climate-related health impacts.
Key point: The open-access journal is expected to publish its inaugural issue in October 2026, with no article processing charges during its first two years.
Implication: Could expand dissemination of implementation-oriented global health research.

📟 PharmaSens reports first-in-human integrated patch pump data [5] [Switzerland • 10 Apr 2026]

https://www.prnewswire.com/news-releases/data-published-in-journal-of-diabetes-science-and-technology-from-first-in-human-study-evaluating-the-feasibility-of-integrated-insulin-delivery-and-glucose-monitoring-using-an-insulin-patch-pump-302739295.html
Context: PharmaSens published feasibility data for its niia investigational patch pump integrating insulin delivery with glucose sensing at the infusion site in adults with type 1 diabetes.
Key point: The study reported feasibility, clinically acceptable glucose monitoring performance, and no insulin delivery failures or adverse events in analyzed participants.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🧬 TIGAR shows protective signal in glucocorticoid-induced osteoporosis models [6] [11 Apr 2026]

https://www.miragenews.com/tigar-mitigates-glucocorticoid-induced-1653604/
Context: A Genes & Diseases study described TIGAR as a protective factor in glucocorticoid-induced osteoporosis across in vitro and in vivo models.
Key point: The researchers linked TIGAR activity to autophagy-dependent Nrf2 signaling, reduced oxidative stress and improved osteoblast function under dexamethasone exposure.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💊 Alembic Pharma wins USFDA approval for generic dapagliflozin [7] [India • 07 Apr 2026]

https://www.cnbctv18.com/market/alembic-pharma-share-price-gains-4-pc-on-usfda-nod-for-key-diabetes-drug-ws-l-19881985.htm
Context: Alembic Pharmaceuticals said it received final USFDA approval for dapagliflozin tablets, 5 mg and 10 mg, equivalent to AstraZeneca’s Farxiga.
Key point: The filing said Alembic was among first paragraph IV ANDA applicants and is eligible for 180 days of shared exclusivity in the US market.
Implication: Introduces competition that may affect pricing and formulary access.

💊 Aurobindo Pharma also clears USFDA for generic dapagliflozin [8] [India • 07 Apr 2026]

https://www.theweek.in/wire-updates/business/2026/04/07/aurobindo-pharma-gets-usfda-nod-for-generic-dapagliflozin-tablets.html
Context: Aurobindo Pharma received final USFDA approval for dapagliflozin tablets, 5 mg and 10 mg, referencing AstraZeneca’s Farxiga.
Key point: The company said it is eligible for 180 days of shared generic marketing exclusivity and plans immediate launch from its Unit-IV facility.
Implication: Introduces competition that may affect pricing and formulary access.

Why It Matters

Denosumab competition is widening in both Canada and the US, with Apotex and Biocon adding biosimilar options in bone health [1][2].
Diabetes device innovation remains focused on reducing hardware burden, with PharmaSens testing a combined pump-CGM form factor [5].
Metabolic and endocrine pipelines continue to converge, illustrated by Insilico’s NR3C1 program spanning oncology, hypercortisolism and obesity [3].
Generic dapagliflozin approvals could reshape SGLT2 pricing and access dynamics in the US market [7][8].
Publication infrastructure is also evolving, with Fast-Track Health and MDPI launching a new global health outlet [4].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What is DENOZA from Apotex?

DENOZA is Apotex’s denosumab injection biosimilar to Prolia. Health Canada approved it for authorized indications, including osteoporosis in high-risk postmenopausal women and men [1].

What are Bosaya and Aukelso from Biocon?

Bosaya and Aukelso are denosumab-kyqq biosimilars to Prolia and Xgeva, respectively. Biocon said both are now commercially available in the US and previously received interchangeable designation from the FDA [2].

What is ISM6200 from Insilico Medicine?

ISM6200 is a preclinical NR3C1 inhibitor nominated by Insilico Medicine for ovarian cancer, hypercortisolism and obesity. The source describes preclinical efficacy and lower projected drug-drug interaction risk, but this is not yet clinical proof [3].

What did the PharmaSens niia study show?

The first-in-human feasibility study supported integrated insulin delivery and glucose sensing in a single wearable device. The source reported clinically acceptable accuracy, no insulin delivery failures and no adverse events in analyzed participants [5].

Why do Alembic Pharma and Aurobindo Pharma matter here?

Both companies disclosed final USFDA approval for generic dapagliflozin tablets, referencing Farxiga. Each also said it qualifies for 180 days of shared exclusivity as a first paragraph IV filer or among the first applicants [7][8].

What is the Journal of Fast-Track Health?

It is a new open-access, peer-reviewed journal from Fast-Track Health in partnership with MDPI. The launch is aimed at connecting urban and national health responses, with an inaugural issue planned for October 2026 [4].

Entities / Keywords

Apotex, DENOZA, denosumab, Prolia, Health Canada, osteoporosis
Biocon, Bosaya, Aukelso, denosumab-kyqq, Xgeva, interchangeable biosimilar
Insilico Medicine, ISM6200, NR3C1, glucocorticoid receptor, Cushing’s syndrome, obesity, ovarian cancer
Fast-Track Health, MDPI, Journal of Fast-Track Health, open-access publishing
PharmaSens, niia, insulin patch pump, continuous glucose monitoring, CGM, type 1 diabetes
TIGAR, glucocorticoid-induced osteoporosis, GIOP, Nrf2, oxidative stress, osteoblast
Alembic Pharma, Aurobindo Pharma, dapagliflozin, Farxiga, SGLT2 inhibitor, ANDA, paragraph IV